Filip Janku Sells 5,407 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 5,407 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $24.50, for a total value of $132,471.50. Following the completion of the transaction, the insider directly owned 60,612 shares in the company, valued at approximately $1,484,994. The trade was a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Filip Janku also recently made the following trade(s):

• On Monday, June 29th, Filip Janku sold 6,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $22.95, for a total value of $137,700.00.
• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.22, for a total value of $239,505.90.
• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $21.42, for a total value of $642,600.00.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE stock opened at $24.21 on Friday. The stock’s 50-day simple moving average is $19.30 and its 200-day simple moving average is $18.84. The firm has a market capitalization of $2.05 billion, a PE ratio of -16.36 and a beta of 1.56. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $4.12 and a fifty-two week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The firm had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $10.95 million. Sell-side analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on GLUE shares. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Guggenheim increased their price objective on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. JPMorgan Chase & Co. boosted their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Finally, Wells Fargo & Company lowered their price objective on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.33.

Institutional Trading of Monte Rosa Therapeutics

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Monte Rosa Therapeutics by 8.6% during the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after buying an additional 257,547 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in Monte Rosa Therapeutics in the 4th quarter valued at $778,000. Strs Ohio purchased a new stake in Monte Rosa Therapeutics in the 4th quarter worth $566,000. Baader Bank Aktiengesellschaft acquired a new position in Monte Rosa Therapeutics during the fourth quarter worth $172,000. Finally, CWM LLC raised its position in Monte Rosa Therapeutics by 13.6% during the fourth quarter. CWM LLC now owns 29,444 shares of the company’s stock worth $462,000 after acquiring an additional 3,536 shares during the period. 79.96% of the stock is owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.